Effect of Adjuvant Conbercept on Patients with Macular Edema Induced by Diabetic Retinopathy and Retinal Vein Occlusion Undergoing Laser Treatment: Impact on Symptom Improvement

Le résumé fourni par la source

Objective: To evaluate the effect of adjuvant Conbercept in patients with macular edema caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) undergoing laser therapy, and its impact on symptom improvement. Methods: This retrospective cohort study analyzed 63 patients treated between January 2022 and January 2025. Patients were assigned to a control group (n=31, laser alone) or an observation group (n=32, laser plus Conbercept). Outcomes included clinical efficacy, symptom improvement time (fundus hemorrhage absorption, exudate absorption, macular edema resolution), best corrected visual acuity (BCVA), retinal thickness (central fovea, superior, nasal, inferior, temporal), and adverse events. Results: The total effective rate was higher in the observation group (96.88%) than in the control group (74.19%) (P<0.05). Symptom improvement times were shorter in the observation group: fundus hemorrhage absorption (2.32±0.25 vs 3.23±0.37 weeks), exudate absorption (10.23±1.38 vs 12.19±1.46 weeks), and macular edema resolution (4.31±0.32 vs 5.69±0.43 weeks) (all P<0.05). BCVA improved significantly in both groups at 1 and 3 months, with greater improvement in the observation group (P<0.05). Retinal thickness decreased in all measured regions in both groups, with more pronounced reductions in the observation group (P<0.05). Adverse event rates did not differ significantly (9.38% vs 12.90%, P>0.05). Conclusion: Conbercept adjunctive to laser therapy in DR- or RVO-related macular edema enhances clinical efficacy, accelerates symptom resolution, improves visual and retinal function, and does not increase adverse reaction risk.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.